Programme 01
High-Risk Medicines — safer prescribing, every patient.
Defined cohorts. Clear interventions. Measurable safety outcomes — across DOACs, methotrexate, lithium, opioids and DMARDs.
Cohort
Who's in scope.
- All patients on DOACs
- All patients on methotrexate, lithium, amiodarone
- Patients on long-term opioid prescriptions
- DMARDs and other locally flagged high-risk groups
Interventions
What we do.
- Register validation and gap analysis
- Monitoring recall and chase
- Bloods review and prescribing action
- MHRA alert action and patient comms
- CQC-ready audit trail per drug group
Typical first-year outcomes
Measured monthly in the BCS Impact Dashboard.
>95%
Monitoring compliance
−40%
Patients overdue
100%
MHRA actioned within SLA
0
Avoidable safety incidents
Talk to our Service Development team
30-minute discovery call. We'll show you how BCS maps to your PCN's specific priorities.